Bracco News 
and Press Center 

VueJect^® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging

Bracco's new BubbleGen technology streamlines cell therapy manufacturing for one-step cell separation and activation with no magnetic residuals. 

Multi-year research agreement aims to advance innovation in MRI, CT, Ultrasound and PET/CT imaging.

Facility upgrades support clinical-grade manufacturing of Bracco’s microbubble-based cell selection and activation technology. GMP readiness expected mid-2027.

Bracco Imaging today announced its first expansion into the cell therapy space, driven by its expertise and newly developed applications of its long-established microbubble technology.

Bracco’s gadopiclenol delivers effective contrast enhancement at half the gadolinium dose compared to other macrocyclic GBCAs.

FDA Approval of VUEWAY^® (gadopiclenol) injection Imaging Bulk Package (IBP) Enhances Options for Efficient, Sustainable MRI Contrast Delivery.

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that more than three million doses¹ of its magnetic resonance imaging (MRI) agent, VUEWAY^® (gadopiclenol) solution for injection, intravenous use, have been administered across 902 customer sites.²

Provided by Business Wire - 25 November 2025

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, will showcase a bold vision for radiology at the Radiological Society of North America (RSNA) 2025 Annual Meeting, to be held November 30 – December 4 in Chicago, Illinois.

Bracco Diagnostics Inc. announced today that the results of a nationwide real-world study, published by Dr. Strom et al. in the Journal of the American Heart Association on 14 May 2025, provide valuable information on safety outcomes of cardiac ultrasound procedures in contemporary practice in the United States.

Bracco Diagnostics Inc. announced today significant upgrades to its innovative HeartSee^TM software, a leading diagnostic tool used in myocardial blood flow (MBF) quantification with cardiac positron emission tomography (PET) imaging.

Bracco Imaging announced today that the U.S. FDA has granted Fast Track designation for the development of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection for detecting areas of active bowel inflammation in patients with Crohn's disease.

Bracco Diagnostics expands its VARIBAR® product line with barium sulfate MINIS for improved diagnostic swallow studies and patient compliance.

Bracco Diagnostics Inc. Branded Max 3^TM, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio.

To learn more, visit Bracco’s booth #3300 at the Radiological Society of North America (RSNA) 2024 Annual Meeting, to be held from December 1-5 in Chicago, Illinois

Bracco Diagnostics Inc. is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY^® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.

Explore the advanced diagnostic imaging solutions Bracco presented at RSNA 2024, including contrast agents, injectors, and AI-driven tools.

Bracco announces FDA clearance for AiMIFY™ software, improving efficiency in molecular imaging interpretation and workflow.

Discover Bracco’s participation at RSNA 2024, showcasing groundbreaking diagnostic imaging solutions and educational programs for radiologists worldwide.
 

Discover Bracco’s launch of CitraClear™, a preprocedure hydration beverage designed with patients in mind.

Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

Meet the innovators recognized by Applied Radiology’s “Leaders on the Horizon” program and how they’re shaping the future of medical imaging.

Join Bracco at RSNA 2023 to explore our latest innovations in medical imaging, including AI-driven tools and advanced contrast agents.
 

Learn about Bracco’s iodine recollection pilot program and Re.Viva initiative, advancing sustainability and circular economy in diagnostic imaging.

Discover why ACR designated Gadopiclenol as a Group II agent and what this means for patient safety and diagnostic accuracy in MRI imaging.

A new survey reveals that 55% of radiologists are concerned about contrast agent supply—see how Bracco addresses these critical challenges in healthcare.

Bracco provides a temporary importation of Iomeron® contrast agent to address supply challenges and ensure continuity in patient care.

Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception.

Bracco Imaging and Guerbet have a worldwide collaboration on Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).

Trieste Next Festival: Diana Bracco and Gianvito Vilé talk about scientific research and the brain drain.

Stay plugged in to the latest developments—for radiologists, imagine: rather than generating a text report for a referring physician, you could show them your workstation directly.

Is AI the elephant in the radiology suite? A 2019 report from the Dana-Farber Cancer Institute showcased an artificial intelligence tool that performed as well as human reviewers—and much more rapidly.

Explore why nuclear medicine is projected to reach over $12B by 2025 and Bracco’s role in shaping the future of diagnostic and therapeutic imaging solutions.